By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ortho-McNeil Pharmaceutical, Inc. 

Raritan  New Jersey    U.S.A.
Phone: 800-682-6532 Fax:



Company News
Ortho-McNeil Pharmaceutical, Inc. Ditches $625 Million Diabetes Drug Pact with Diamyd Medical AB 6/2/2011 8:24:34 AM
Ortho-McNeil Pharmaceutical, Inc. Enters into Agreement with Watson Laboratories, Inc. (WPI) for CONCERTA(R) Authorized Generic 11/2/2010 7:34:57 AM
Metabolex, Inc. Enters Into Type 2 Diabetes Development and License Agreement with Ortho-McNeil Pharmaceutical, Inc.; Metabolex Could be Eligible to Receive Development, Regulatory, and Commercial Milestones up to $330 Million 6/22/2010 7:15:21 AM
Ortho-McNeil Pharmaceutical, Inc. Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million 5/24/2010 8:05:57 AM
Ortho-McNeil Pharmaceutical, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities 4/29/2010 11:39:29 AM
FDA Issues Complete Response Letter for Ortho-McNeil Pharmaceutical, Inc.'s Rivaroxaban 5/28/2009 9:53:22 AM
Ortho-McNeil Pharmaceutical, Inc. New Study Supports Use of LEVAQUIN as a Guideline-Concordant Antibiotic for the Treatment of Community-Acquired Pneumonia 10/27/2008 8:42:00 AM
Isis Pharmaceuticals, Inc. (ISIS)Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil Pharmaceutical, Inc. 10/2/2007 10:33:00 AM
FDA Approves Ortho-McNeil Pharmaceutical, Inc.'s LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 9/17/2007 6:57:52 AM
Isis Pharmaceuticals, Inc. (ISIS) Licenses Experimental Diabetes Drugs to Ortho-McNeil Pharmaceutical, Inc. for $45 Million 9/13/2007 7:08:45 AM